期刊
DRUG DISCOVERY TODAY
卷 24, 期 9, 页码 1720-1724出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2019.06.003
关键词
-
资金
- ORCHID consortium
- EU's Horizon 2020 research and innovation program [766884]
Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and its potential quantitative impact. We find that the technology has the potential to reduce R&D costs significantly, driven by changes in direct costs, success rates and the length of the R&D process. Finally, we discuss regulatory challenges to efficiency improvements.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据